We would love to hear your thoughts about our site and services, please take our survey here.
Evening Hors, I do indeed and yes he must have known. I’ll take a trip down Rodeo Drive anyday! For once it would be nice to have a crystal ball to see where this is 12 months ahead, and no Brexit or China trade concerns (other than general market effects). Interesting times ahead from Sept onwards, enjoy.
Afternoon Hors, I think you are right. What we need are details of the extent of the contract and the effect it will have on income, then the market will react. Is there likely to be a user subscription service? If so then a regular update of subscribers would be good. Should be huge for FDBK but many unknowns still.
Looks like normal trader patterns today and I suspect, in the absence of further news, we will see a range of 0.017 - 0.0195 for a couple of weeks. As we get nearer September it’s possible the sp will rise above 2p in anticipation of an announcement at or before the Expo, imo. After that the sp could be anything depending upon the detail given regarding contracts/income. Not forgetting the Strategic Review Part2 of course. Interesting times, dyor.
Jarv I have been a lth for many years and without doubt that TO interview is streets ahead of any other I have heard. Certainly worth listening to again and again. This is an incredible opportunity for FDBK which will totally transform the company imo. It is difficult to grasp how big this could become....so no silly sp predictions from me, and in the absence of a takeover I will not sell a share over the next couple of years. Exciting times imo, dyor.
Nice message, hopefully there will be a formal tie up with the NHS and a strong recommendation/direction to use the service. Should be a no brainer from a security viewpoint alone plus the clinical benefits. Wonder how it will be costed, individual usage or via Trusts?
Was it a genuine sale, was it borrowed stock,? Would expect a tr1 unless sold almost total holding, and reported very late. Defies logic to sell at that price use when strong news and a rerate likely soon. Any thoughts, I really dislike very large illogical trades. Wonder if FDBK were aware or identified the seller. What range of overhang do we have now El iyo?
Very strong buying today so where is the large sell that was assumed to take the sp down yesterday despite heavy buying then? Strange patterns for trades, suspicion abounds....come on mms play fair! Let’s have an orderly market.
Even Merlin would have difficulty predicting next weeks movement. We went from plentiful supply of shares at the start of this week to almost none available on Friday. Despite heavy buying pressure the sp tanked at the end. Will a large sell order going back to Thursday/ Friday be announced early Monday? If mms get their hands on shares will the sp rise quickly to fill buy orders? If there remain few on offer will mms raise the sp to encourage sales or lower further to scare holders into selling? For sure FDBK will not be happy at what appears to be a disorderly trend and must be investigating the cause. The sp next Friday, without any news, could be anything from 0.005 to 0.015 imo your guess is as good as mine.
Evening folks
The strange sp movements and trading volumes of the past few days do not change the prospects for future growth following Tom Oakley’s recent Review. So much as I dislike large unknowns I am still interested in buying at these distressed levels based on the hopes for mobile imaging. Still would like to know what is behind all this though.
Hi folks, there does seem to be a lot of stock still available despite the high volumes of the last week. El has said 1-2million available at 1p. Not sure where it all comes from BUT if the Cadran mobile system is delivered Q3-4 and positive NHS contract ensues, as well as the TexRAD update is positive then I don’t imagine current sp levels will be seen again. If everything lines up this could easily double or more by year end imo, but dyor. I am a buyer at these prices, especially into the current overhang!
Yes Bo, what an excellent interview! My faith is renewed. Tom Oakley gives a very precise, detailed summary of where he wants FDBK to go. Cadran will be huge in the NHS and there is clearly scope for international sales. TexRAD is to have an improved product line and when his review of this area is completed we can expect details of how it will be positioned for clinical uptake. There is also a pledge to regularly update shareholders on developments, an admission that we have been neglected for too long.
A very refreshing interview all round imho.